Ailanthone:a new potential drug for castration-resistant prostate cancer

• 作 者: Shihong Peng Zhengfang Yi Mingyao Liu
• 机 构: East China Normal University and Shanghai Fengxian District Central Hospital Joint Center for Transl
• 出 处: Chinese Journal of Cancer
• 发表日期: 2017年05期
• 关键词: androgen initially deprivation eventually burden temporary targeting suppressed

Prostate cancer(PCa)is the most common male cancer[1,2].PCa initially depends on androgen receptor(AR)signaling for growth and survival.Androgen deprivation therapy causes a temporary reduction in PCa tumor burden,but the tumor eventually develops into castration-resistant prostate cancer(CRPC)with the ability to grow

Prostate cancer (PCa) is the most common male cancer [1,2]. PCa initially depends on androgen receptor (AR) signaling for growth and survival. Androgen deprivation therapy causes a temporary reduction in PCa tumor burden, but the tumor eventually development into castration-resistant prostate cancer (CRPC) with the ability to grow